$%^STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1646jxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:21:09 ON 08 APR 2008

=> file medline embase caplus uspatful biosis
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.42 0.42

FILE 'MEDLINE' ENTERED AT 09:22:03 ON 08 APR 2008

FILE 'EMBASE' ENTERED AT 09:22:03 ON 08 APR 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 09:22:03 ON 08 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:22:03 ON 08 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:22:03 ON 08 APR 2008
Copyright (c) 2008 The Thomson Corporation

=> s (interferon-beta or IFN-beta or (interferon (w) beta))
L1 41061 (INTERFERON-BETA OR IFN-BETA OR (INTERFERON (W) BETA))

=> s (glomerulonephritis or (chronic (w) renal (w) failure))
L2 156499 (GLOMERULONEPHRITIS OR (CHRONIC (W) RENAL (W) FAILURE))

=> s l1 (s) l2
L3 27 L1 (S) L2

=> duplicate remove l3
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, CAPLUS, USPATFULL, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L3
L4 23 DUPLICATE REMOVE L3 (4 DUPLICATES REMOVED)

=> d l4 1- ibib, abs
YOU HAVE REQUESTED DATA FROM 23 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2007462088 MEDLINE <<LOGINID::20080408>>
DOCUMENT NUMBER: PubMed ID: 17679741
TITLE: ***Interferon*** ***beta*** for ***glomerulonephritis*** ?.
AUTHOR: Wardle E Nigel
SOURCE: Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, (2007 Sep) Vol. 18, No. 3, pp. 333-6.
Journal code: 9436968. ISSN: 1319-2442.
PUB. COUNTRY: Saudi Arabia
DOCUMENT TYPE: Editorial
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200801
ENTRY DATE: Entered STN: 8 Aug 2007
Last Updated on STN: 18 Jan 2008
Entered Medline: 17 Jan 2008
AB Interferon beta (IFNbeta) is used in the therapy of multiple sclerosis (MS), which develops from the activation of autoreactive T lymphocytes against peptides of myelin basic protein. IFNbeta was demonstrated to have beneficial effects in experimental models of glomerulonephritis (GN), such as decreasing proteinuria via Il-10 release. T helper (Th-1) lymphocyte responses are reduced, the actions of metalloproteinase (MMP9) are suppressed, and the functions of regulatory T cells are promoted. In concept, IFNI3 therapy might be beneficial in patients with life threatening forms of GN, such as Goodpasture's syndrome or vasculitis. Further research is warranted to study the effect of IFNbeta on GN in clinical settings.

L4 ANSWER 2 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:296967 USPATFULL <<LOGINID::20080408>>

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ballance, David J., Berwyn, PA, UNITED STATES
Turner, Andrew J., King Of Prussia, PA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
Delta Biotechnology Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007259815	A1	20071108
APPLICATION INFO.:	US 2007-783419	A1	20070409 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2006-429373, filed on 8 May 2006, GRANTED, Pat. No. US 7238667 Continuation of Ser. No. US 2004-775204, filed on 11 Feb 2004, GRANTED, Pat. No. US 7141547 Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411426P	20020918 (60)
	US 2002-411355P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP,
901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 24746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:210712 USPATFULL <<LOGINID::20080408>>
TITLE: Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
INVENTOR(S): Tangri, Shabnam, San Diego, CA, UNITED STATES
Mothe, Bianca, Oceanside, CA, UNITED STATES
Sette, Alessandro, La Jolla, CA, UNITED STATES
Southwood, Scott, Santee, CA, UNITED STATES
Briggs, Kristen, Del Mar, CA, UNITED STATES
Chesnut, Robert W., Cardiff-by-the-Sea, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007184519	A1	20070809
APPLICATION INFO.:	US 2004-550675	A1	20040402 (10)
	WO 2004-US10353		20040402
			20060522 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459939P	20030402 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL
ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1-26
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 7103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention provides peptides, polypeptides, proteins and/or antibodies of reduced immunogenicity. Also provided are methods of reducing the immunogenicity of peptides, polypeptides, proteins and/or antibodies. In certain embodiments, the immunogenicity of therapeutic peptides, polypeptides, proteins, and/or antibodies such as hormones, growth factors, and cytokines is reduced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:88629 USPATFULL <<LOGINID::20080408>>
TITLE: Stem cell expansion and uses
INVENTOR(S): Reading, Christopher L., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Dowding, Charles, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007077201	A1	20070405
APPLICATION INFO.:	US 2006-389294	A1	20060325 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2005-241670, filed on 29 Sep 2005, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-614869P	20040929 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL,
SUITE 400, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 18130
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a conditions where cell or tissue repiar is

needed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:37100 USPATFULL <<LOGINID::20080408>>
TITLE: Cytokine receptor
INVENTOR(S): Varghese, Joseph Noozhumutry, Victoria, AUSTRALIA
Simpson, Richard J., Richmond, AUSTRALIA
Moritz, Robert Lorenz, Victoria, AUSTRALIA
Lou, Meizhen, Victoria, AUSTRALIA
Ji, Hong, Victoria, AUSTRALIA
Branson, Kim Matthew, Victoria, AUSTRALIA
Smith, Brian John, Victoria, AUSTRALIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007032640	A1	20070208
APPLICATION INFO.:	US 2002-489705	A1	20020916 (10)
	WO 2002-AU1255		20020916
			20040520 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AU 2001-7695	20010914

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW,
WASHINGTON, DC, 20007, US
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5605
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A crystalline composition comprising a crystal of the IL-6 receptor I chain is provided. Also provided are methods of using the crystal and related structural information to screen for and design compounds that interact with IL-6R, or variants thereof. Also provided are methods of modulating an IL-6 receptor comprising contacting the IL-6 receptor with a compound identified by the screening method of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:29699 USPATFULL <<LOGINID::20080408>>

TITLE: Therapies for renal failure using interferon-beta
INVENTOR(S): Lobb, Roy R., Westwood, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007025965	A1	20070201
APPLICATION INFO.:	US 2003-521513	A1	20030717 (10)
	WO 2003-US22440		20030717
			20051118 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396393P	20020717 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1-69
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 3109
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, ***glomerulonephritis*** or ***chronic*** ***renal*** ***failure*** . The methods involve the administration of ***IFN*** -. ***beta*** . therapeutics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:17006 USPATFULL <<LOGINID::20080408>>
TITLE: Steroid analogs and characterization and treatment methods
INVENTOR(S): Reading, Christopher L., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Dowding, Charles, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007014719	A1	20070118
APPLICATION INFO.:	US 2005-241670	A1	20050929 (11)

	NUMBER	DATE

PRIORITY INFORMATION: US 2004-614869P 20040929 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL,
SUITE 400, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 24267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods to characterize exemplified compounds such as 3.beta., 17.beta.-dihydroxyandrost-1,5,11 -triene and 3.beta., 17.beta.-dihydroxy-17.alpha.-ethynylandrost-1,5,11-triene and to the use of described compounds to ameliorate or treat a condition such as thrombocytopenia, inflammation or other exemplified conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 23 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2007636673 MEDLINE <<LOGINID::20080408>>
DOCUMENT NUMBER: PubMed ID: 17942968
TITLE: ***Interferon*** - ***beta*** reduces proteinuria in experimental ***glomerulonephritis*** .
AUTHOR: Satchell Simon C; Buchatska Olena; Khan Sarah B; Bhangal Gurjeet; Tasman Candida H; Saleem Moin A; Baker Darren P; Lobb Roy R; Smith Jennifer; Cook H Terence; Mathieson Peter W; Pusey Charles D
CORPORATE SOURCE: Academic Renal Unit, University of Bristol, Southmead Hospital, Bristol, UK.. s.c.satchell@bristol.ac.uk
CONTRACT NUMBER: 075731
SOURCE: Journal of the American Society of Nephrology : JASN, (2007 Nov) Vol. 18, No. 11, pp. 2875-84. Electronic Publication: 2007-10-17.
Journal code: 9013836. E-ISSN: 1533-3450.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200712
ENTRY DATE: Entered STN: 27 Oct 2007
Last Updated on STN: 14 Dec 2007
Entered Medline: 13 Dec 2007
AB Interferon-beta (IFN-beta) is a multifunctional cytokine with immunomodulatory properties. We examined the effect of IFN-beta in three separate rat models of glomerular injury and in cultured human glomerular

endothelial cells and podocytes. In nephrotoxic nephritis in WKY rats, recombinant rat IFN-beta started either at induction or after establishment of disease significantly reduced 24-h proteinuria by up to 73% and 51%, respectively, but did not affect serum creatinine. There was a slight reduction in numbers of glomerular macrophages, but no difference in glomerular or tubulointerstitial scarring. In Thy-1 nephritis in Lewis rats, IFN-beta started at induction of disease reduced proteinuria by up to 66% with no effect on numbers of glomerular macrophages, but a reduced number of proliferating cells. In puromycin nephropathy in Wistar rats, IFN-beta started at induction of disease reduced proteinuria by up to 93%, but had no effect on glomerular histology. In cultured cells, human IFN-beta-1a had a dramatic effect on barrier properties, increasing electrical resistance across monolayers of either glomerular endothelial cells or podocytes and decreasing trans-monolayer passage of albumin. In conclusion, these results show that IFN-beta reduces proteinuria in three different rat models of glomerular injury and that its anti-proteinuric action may result from direct effects on cells that comprise the glomerular filtration barrier. These data indicate that IFN-beta may have potential as a therapeutic agent in proteinuric renal disease.

L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1353338 CAPLUS <<LOGINID::20080408>>
DOCUMENT NUMBER: 148:182185
TITLE: Interferon-.beta.: a novel way to treat nephrotic syndrome?
AUTHOR(S): Rees, Andrew J.; Kain, Renate
CORPORATE SOURCE: Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria
SOURCE: Journal of the American Society of Nephrology (2007), 18(11), 2797-2798
CODEN: JASNEU; ISSN: 1046-6673
PUBLISHER: American Society of Nephrology
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The research of Satchell et al. (2007) entitled " ***Interferon*** - ***beta*** reduces proteinuria in three distinct models of exptl. ***glomerulonephritis*** and enhances barrier properties of glomerular endothelial cell and podocyte monolayers" is reviewed with commentary and refs. Satchell et al. describes the effect of ***IFN*** -. ***beta*** .1a in models of ***glomerulonephritis*** is different for at least three reasons: (1) It identifies a potential renal use for a cytokine already commonly applied in the clinic for other diseases; (2) it documents a striking redn. in proteinuria; and (3) it includes in vitro studies with glomerular endothelial cells and podocytes that not only provide a possible explanation for the in vivo results but also raise questions about the

nature of the glomerular filtration barrier.

L4 ANSWER 10 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2006:322351 USPATFULL <<LOGINID::20080408>>
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006276396	A1	20061207
	US 7238667	B2	20070703
APPLICATION INFO.:	US 2006-429373	A1	20060508 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-775204, filed on 11 Feb 2004, PENDING Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411355P	20020918 (60)
	US 2002-411426P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP,
901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 24781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2006:228368 USPATFULL <<LOGINID::20080408>>
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ballance, David J., Berwyn, PA, UNITED STATES
Turner, Andrew J., King of Prussia, PA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
Delta Biotechnology Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006194735	A1	20060831
APPLICATION INFO.:	US 2006-429276	A1	20060508 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-775204, filed on 11 Feb 2004, PENDING Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)

US 2002-351360P 20020128 (60)
US 2002-359370P 20020226 (60)
US 2002-360000P 20020228 (60)
US 2002-367500P 20020327 (60)
US 2002-370227P 20020408 (60)
US 2002-378950P 20020510 (60)
US 2002-382617P 20020524 (60)
US 2002-383123P 20020528 (60)
US 2002-385708P 20020605 (60)
US 2002-394625P 20020710 (60)
US 2002-398008P 20020724 (60)
US 2002-402131P 20020809 (60)
US 2002-402708P 20020813 (60)
US 2002-411355P 20020918 (60)
US 2002-411426P 20020918 (60)
US 2002-414984P 20021002 (60)
US 2002-417611P 20021011 (60)
US 2002-420246P 20021023 (60)
US 2002-423623P 20021105 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP,
901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 24486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2006:214562 USPATFULL <<LOGINID::20080408>>
TITLE: Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-ss

INVENTOR(S): Sandrock, Alfred, Newton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006182715	A1	20060817
APPLICATION INFO.:	US 2003-529522	A1	20030926 (10)
	WO 2003-US30532		20030926
			20060213 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-414307P	20020927 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD., BOSTON, MA, 02210-2600, US
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-.beta. therapeutics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2006:98549 USPATFULL <<LOGINID::20080408>>
TITLE: Interferon beta-like molecules for treatment of stroke
INVENTOR(S): Glazer, Steven, Copenhagen N, DENMARK
Sager, Thomas, Smoerum, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006083715	A1	20060420
APPLICATION INFO.:	US 2003-506954	A1	20030228 (10)
	WO 2003-DK127		20030228
			20050609 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2002-371	20020312

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515
GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1-7
LINE COUNT: 2700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to use of interferon beta-like polypeptides for treatment of stroke or transient ischemic attach in a primate, preferably in a human. More particularly, the interferon beta-like polypeptides differs from the amino acid sequence of wild-type human IFNB (SEQ ID NO:2) in that at least one glycosylation site, preferably at least one in vivo N-glycosyltaion site has been introduced. Optionally the interferon beta-like polypeptides are PEGylated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2006:43270 USPATFULL <<LOGINID::20080408>>
TITLE: Pharmaceutical materials and methods for their preparation and use
INVENTOR(S): Chmielewski, Jean A., Lafayette, IN, UNITED STATES
Kahr, Bart E., Seattle, WA, UNITED STATES
Lewis, Jerry, Carmel, IN, UNITED STATES
PATENT ASSIGNEE(S): Purdue Research Foundation, West Lafayette, IN, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7001892	B1	20060221
	WO 2000076480		20001221
APPLICATION INFO.:	US 2001-18043		20000612 (10)
	WO 2000-US16140		20000612
	20020521 PCT 371 date		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-138912P	19990611 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Maier, Leigh C.
LEGAL REPRESENTATIVE: Woodard, Emhardt, Moriarty, McNett & Henry LLP
NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions comprising crystals of a pharmaceutically-acceptable crystal lattice component, and an active pharmaceutical ingredient different from and included within the crystal lattice component in a growth-sector specific orientation. The crystals are prepared using components and methods which yield crystals having suitable purity and efficacy for use in administering the active pharmaceutical ingredients to a patient. The crystals are typically combined with adjuvants such as excipients, diluents or carriers, and are preferably formulated into tablets, capsules, suspensions, and other conventional forms containing predetermined amounts of the pharmaceuticals. Also provided are methods for preparing the crystals, and methods for storing and administering the active pharmaceutical ingredient either included within the crystals or upon reconstitution of the crystals to a solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:60234 CAPLUS <<LOGINID::20080408>>
DOCUMENT NUMBER: 140:127206
TITLE: ***Interferon*** . ***beta*** . and human IgG1 Fc chimeric proteins for treating ***glomerulonephritis*** and ***chronic*** ***renal*** ***failure***
INVENTOR(S): Lobb, Roy R.
PATENT ASSIGNEE(S): Biogen Inc., USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006756	A2	20040122	WO 2003-US22440	20030717
WO 2004006756	A3	20040819		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2492649 A1 20040122 CA 2003-2492649 20030717
AU 2003256603 A1 20040202 AU 2003-256603 20030717
EP 1553971 A2 20050720 EP 2003-764795 20030717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1681527 A 20051012 CN 2003-822107 20030717
JP 2005537269 T 20051208 JP 2004-521961 20030717
NZ 538217 A 20070427 NZ 2003-538217 20030717
BR 2003012947 A 20070710 BR 2003-12947 20030717
ZA 2005000342 A 20060726 ZA 2005-342 20050113
MX 2005PA00658 A 20050819 MX 2005-PA658 20050114
NO 2005000827 A 20050415 NO 2005-827 20050216
US 20070025965 A1 20070201 US 2005-521513 20051118
PRIORITY APPLN. INFO.: US 2002-396393P P 20020717
WO 2003-US22440 W 20030717

AB The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, glomerulonephritis or chronic renal failure. The methods involve the administration of IFN-.beta. therapeutics.

L4 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:282418 CAPLUS <<LOGINID::20080408>>
DOCUMENT NUMBER: 138:270306
TITLE: Use of interferon .beta. in the therapy of systemic lupus erythematosus
INVENTOR(S): Schwarting, Andreas; Galle, Peter R.
PATENT ASSIGNEE(S): Germany
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028753	A1	20030410	WO 2002-DE3669	20020927

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10148417 A1 20030417 DE 2001-10148417 20010929

AU 2002347065 A1 20030414 AU 2002-347065 20020927

PRIORITY APPLN. INFO.: DE 2001-10148417 A 20010929

WO 2002-DE3669 W 20020927

AB Disclosed is the use of ***interferon*** . ***beta*** . for the prodn. of an agent for the prevention and treatment of SLE and improvement of kidney function, ***glomerulonephritis*** , proteinuria, splenomegaly, encephalomyelitis and collagen-induced arthritis, for the prevention of leukocyte infiltration and the prevention of IgG-deposits in kidneys. Said agent is particularly suitable for the treatment of SLE WHO-type IV.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2001:197061 USPATFULL <<LOGINID::20080408>>

TITLE: Dithiolin derivatives, their preparation and their therapeutic effect

INVENTOR(S): Fujita, Takashi, Kashiwa, Japan
Yokoyama, Tomihisa, Urawa, Japan

PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6313164	B1	20011106
APPLICATION INFO.:	US 1999-354006		19990715 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52095, filed on 31 Mar 1998, now patented, Pat. No. US 6013663

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-83749	19970402
	JP 1998-8837	19980120

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Huang, Evelyn Mei

LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.

NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
LINE COUNT: 12721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula (I): ##STR1##

wherein one of m and n is 0, and the other is 0, 1 or 2; k is 0 or 1 to 12; R.sup.1 is hydrogen, a substituent which is an aryl or a heterocyclic, or an optionally substituted alkyl group; A is a single bond, an oxygen atom, a carbonyl group or a group of the formula --N(R.sup.2)CO--, --N(R.sup.2)CS--, --N(R.sup.2)SO.sub.2 --, --CON(R.sup.2)N(R.sup.3)CO--, --CON(R.sup.2)CO--, --CON(R.sup.2)CS--, --CON(R.sup.2)SO.sub.2 --, --O--CO--, --ON(R.sup.2)CO--, --ON(R.sup.2)SO.sub.2 --, --O--CON(R.sup.2)N(R.sup.3)CO--, --O--CON(R.sup.2)CO--, --O--CON(R.sup.2)SO.sub.2 --, --CO--O--, --CO--CO--, --CO--CON(R.sup.2)N(R.sup.3)CO--, --CO--CON(R.sup.2)CO--, --CO--CON(R.sup.2)SO.sub.2 --, --N(R.sup.2)O--, --N(R.sup.2)COCO--, --N(R.sup.2)N(R.sup.3)CO--, --N(R.sup.2)N(R.sup.3)SO.sub.2 --, --N(R.sup.2)CON(R.sup.3)N(R.sup.4)CO--, --N(R.sup.2)CON(R.sup.3)CO--, --N(R.sup.2)CON(R.sup.3)SO.sub.2 -- or --N(R.sup.2)CON(R.sup.3)SO.sub.2 N(R.sup.4)CO--, wherein R.sup.2, R.sup.3 and R.sup.4 are the same or different and each is hydrogen, alkyl, aralkyl, acyl or a substituent .alpha.; B is a single bond, or a group of the formula --N(R.sup.5)-- or --N(R.sup.6)N(R.sup.5)-- wherein R.sup.5 and R.sup.6 are the same or different and each is hydrogen, alkyl, aralkyl, acyl or a substituent .alpha., or R.sup.5, together with R.sup.1 and the nitrogen atom to which they are bonded form a heterocyclic ring having from 5 to 7 ring atoms; or R.sup.1 represents a group of formula --OR.sup.7, wherein R.sup.7 is alkyl, alkenyl, aralkyl or a substituent .alpha.; or R.sup.1 represents a hydroxy group or a group of the formula --OR.sup.7 ; or pharmaceutically acceptable salts thereof. The compounds enhance the activity of glutathione reductase and can be used for the treatment and prevention of a variety of diseases including cataracts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:4825 USPATFULL <<LOGINID::20080408>>
TITLE: Dithiolan derivatives, their preparation and their therapeutic effect
INVENTOR(S): Fujita, Takashi, Kashiwa, Japan
Yokoyama, Tomihisa, Urawa, Japan
PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)

NUMBER KIND DATE

---------- ------ --------
PATENT INFORMATION: US 6013663 20000111
APPLICATION INFO.: US 1998-52095 19980331 (9)

NUMBER DATE
---------- --------
PRIORITY INFORMATION: JP 1997-83749 19970402
JP 1998-8837 19980120
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huang, Evelyn Mei
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
LINE COUNT: 9846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I): ##STR1## wherein one of m and n represents 0, and the other represents 0, 1 or 2; k represents 0 or 1 to 12; R.sup.1 is hydrogen, an aryl, a heterocyclic, an alkyl, a hydroxy or --OR.sup.7, wherein R.sup.7 is an alkyl, an alkenyl or an aralkyl; A is --CON(R.sup.2)SO.sub.2--, wherein R.sup.2 is hydrogen, an alkyl or an aralkyl; B is a single bond; and pharmaceutically acceptable salts thereof. The compounds have the ability to enhance the activity of glutathione reductase and can therefore be used for the treatment and prevention of a variety of diseases including cataracts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:391941 CAPLUS <<LOGINID::20080408>>
DOCUMENT NUMBER: 131:72566
TITLE: Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy
AUTHOR(S): Ohta, Satoshi; Yokoyama, Hitoshi; Wada, Takashi; Sakai, Norihiko; Shimizu, Miho; Kato, Tamayo; Furuichi, Kengo; Segawa, Chikako; Hisada, Yukimasa; Kobayashi, Ken-ichi
CORPORATE SOURCE: First Department of Internal Medicine and Division of Blood Purification, Kanazawa University, Kanazawa, 920-8641, Japan
SOURCE: American Journal of Kidney Diseases (1999), 33(6), 1040-1048
CODEN: AJKDDP; ISSN: 0272-6386
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal

LANGUAGE: English

AB We previously reported the glomerular deposition of hepatitis C virus (HCV) core antigen (Ag) in HCV-related nephropathy. In this study, we analyzed 23 HCV-pos. subjects with exacerbation of proteinuria and/or hematuria during interferon (IFN) therapy and measured urinary protein selectivity. We also examd. the involvement of HCV-related Ag using anti-HCV core (capside) Ag murine monoclonal antibody (Ab) and anti-core2 rabbit polyclonal Abs in nine subjects. Of 17 subjects, 13 (78%) showed low selective proteinuria. We found mesangial proliferative glomerulonephritis in 9 subjects, membranoproliferative glomerulonephritis in 1 subject, and nephrosclerosis in 1 subject. Immunofluorescence study showed the glomerular deposition of IgG (IgG) or IgA and complements in all 9 subjects examd. Trace amts. only of HCV core Ag were detected along the glomerular capillary wall in 3 of 9 subjects (33%). Electron microscopy showed subendothelial or mesangial electron-dense deposits and also foot process effacement (20% to 72.5% of glomerular capillary walls) in all subjects and endothelial swelling in 4 subjects. In conclusion, IFN therapy for HCV may exacerbate the underlying glomerulopathies, unrelated to HCV Ags, through direct or indirect effects on glomerular endothelial and epithelial cells. Physicians should carefully distinguish HCV-related nephropathy from other glomerular diseases when they administer IFN therapy to HCV-pos. subjects.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 23 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 91186537 MEDLINE <<LOGINID::20080408>>
DOCUMENT NUMBER: PubMed ID: 2082050
TITLE: Clinical and histological observation of HBV ***glomerulonephritis*** treated with ***interferon*** - ***beta*** .
AUTHOR: Ueda T; Gotoh Y; Shiroshita K; Sakurai T; Kataoka Y
CORPORATE SOURCE: Department of Nephrology, Sapporo City General Hospital, Japan.
SOURCE: Nippon Jinzo Gakkai shi, (1990 Nov) Vol. 32, No. 11, pp. 1153-9.
Journal code: 7505731. ISSN: 0385-2385.
PUB. COUNTRY: Japan
DOCUMENT TYPE: (CASE REPORTS)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Japanese
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199105
ENTRY DATE: Entered STN: 26 May 1991

Last Updated on STN: 26 May 1991
Entered Medline: 6 May 1991

AB Hepatitis B virus carriers, a 30-year-old man (case 1) and a 31-year-old man (case 2), associated with nephrotic syndrome were treated with interferon-beta. The nephrotic syndrome did not respond to corticosteroid therapy. Their HBs-Ag, HBe-Ag and HBc-Ab were positive. Renal biopsies revealed membranous glomerulonephritis in case 1 and mixed membranous and proliferative glomerulonephritis in case 2. Direct immunofluorescence studies showed strong granular staining of the GBM with IgG and using sandwich technique with anti-HBe antiserum, granular deposits were seen throughout the GBM. Patients were administrated mainly 3-6 x 10(6) IU/day interferon-beta intravenously for four weeks. After transitory elevation of serum transaminase, HBe-Ag and DNA-polymerase have disappeared with development of HBe-Ab (seroconversion) about six months after the end of interferon-beta administration. Then nephrotic syndrome has recovered in incomplete remission after a year and a half follow-up. The secondary renal biopsy in case 1 showed less intense deposits of HBe-Ag along GBM. These facts suggest that the improvement of proteinuria is associated with the decrease in HBV replication due to interferon therapy.

L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:245757 CAPLUS <<LOGINID::20080408>>
DOCUMENT NUMBER: 114:245757
TITLE: Possible role of IL-6 in pathogenesis of immune complex-mediated glomerulonephritis in NZB/W F1 mice: induction of IgG class anti-DNA autoantibody production
AUTHOR(S): Mihara, Masahiko; Ohsugi, Yoshiyuki
CORPORATE SOURCE: Fuji-Gotemba Res. Lab., Chugai Pharm. Co. Ltd., Gotemba, 412, Japan
SOURCE: International Archives of Allergy and Applied Immunology (1990), 93(1), 89-92
CODEN: IAAAAM; ISSN: 0020-5915
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study demonstrates that interleukin-6 (IL-6) increases the autoantibody prodn. by B cells from NZB/W F1 mice. Splenic B cells were cultured for 5 days in the presence or absence of human IL-6, and then the anti-DNA antibody and Ig contents in the culture supernatants were measured by ELISA. Adding IL-6 increased IgG anti-DNA antibody prodn. by B cells from old mice (30 wk), but not from young ones (17 wk). B cells obtained from both young and old mice produced IgM anti-DNA antibody, which increased when IL-6 was added. The increased anti-DNA antibody prodn. was suppressed by anti-recombinant human IL-6 antibody to the background level, i.e. antibody contents in the absence of IL-6. In contrast, murine IL-5 did not increase IgG anti-DNA antibody prodn.,

although it promoted the prodn. of IgM anti-DNA antibody. Furthermore, when IL-5 was added in combination with IL-6, there was an additive increase in IgM, but not in IgG anti-DNA antibody prodn. Similar results were obtained in the measurement of the Ig contents. These results suggest the possible role of IL-6 in the pathogenesis of autoimmune disease in NZB/W F1 mice.

L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:96739 CAPLUS <<LOGINID::20080408>>
DOCUMENT NUMBER: 112:96739
TITLE: Involvement of IL-6 in mesangial proliferative glomerulonephritis
AUTHOR(S): Horii, Yasuhiro; Muraguchi, Atsushi; Iwano, Masayuki; Matsuda, Tadashi; Hirayama, Toshihide; Yamada, Hiroharu; Fujii, Yoshihiro; Dohi, Kazuhiro; Ishikawa, Hyoe; et al.
CORPORATE SOURCE: Inst. Mol. Cell. Biol., Osaka Univ., Osaka, Japan
SOURCE: Journal of Immunology (1989), 143(12), 3949-55
CODEN: JOIMA3; ISSN: 0022-1767
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This study demonstrated that interleukin-6 (IL-6) was a possible autocrine growth factor for rat mesangial cells (MC). RIL-6 induced in vitro growth of rat MC at a concn. of 2 to 200 ng/mL and IL-6 activity was found in the supernatant of cultured rat MC. Northern blot anal. as well as in situ hybridization revealed that IL-6 mRNA was expressed in the cultured MC. Of urine samples from patients with mesangial proliferative glomerulonephritis (PGN) 50% were found to contain significant IL-6 activity (ranging from 30 to 126 pg/mL). Urine samples from other types of primary glomerular diseases such as minimal change nephrotic syndrome or healthy volunteers contained no detectable IL-6 activity. Only 2 of 27 urine samples from membranous nephropathy contained detectable amt. of IL-6. Furthermore, there was some relationship between the levels of urine IL-6 and the progressive stage of PGN. Finally, by immunohistochem. staining using an anti-IL-6 mAb, it was shown that MC in the affected glomeruli of PGN patients produced IL-6, whereas MC obtained from the patients with membranous nephropathy, minimal change nephrotic syndrome or normal kidney were not found to produce IL-6. These data suggest that deregulated prodn. of IL-6 is involved in PGN and the measurement of urine IL-6 is helpful for the differential diagnosis of PGN as well as for monitoring the progression of PGN.

L4 ANSWER 23 OF 23 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on
STN
ACCESSION NUMBER: 1986:410766 BIOSIS <<LOGINID::20080408>>

DOCUMENT NUMBER: PREV198631086732; BR31:86732
TITLE: MOUSE INTERFERON INDUCES ANEMIA DUE TO DECREASED HEMATOPOIESIS IN SUCKLING MICE.
AUTHOR(S): NEDA K [Reprint author]; KIMURA S; WATANABE S; KAWASAKI H;
NAKAYOSHI H; UTSUMI J; NARUSE N
CORPORATE SOURCE: NRI LIFE SCIENCE, KANAGAWA, JAPAN
SOURCE: Toxicology Letters (Shannon), (1986) Vol. 31, No. SUPPL, pp. 42.
Meeting Info.: FOURTH INTERNATIONAL CONGRESS OF TOXICOLOGY,
TOKYO, JAPAN, JULY 21-25, 1986. TOXICOL LETT (AMST).
CODEN: TOLED5. ISSN: 0378-4274.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 14 Oct 1986
Last Updated on STN: 14 Oct 1986

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 79.13 79.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -4.80 -4.80

STN INTERNATIONAL LOGOFF AT 09:28:54 ON 08 APR 2008